RxDoctor Payments Data

Shireen Kirata

Physician Assistant · Derry, NHNPI 1265941769

Payments from drug & device makers

$1,511in general payments, 2019–2025

Across 40 payments — averaging $37.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$603
  • Johnson & Johnson$203
  • Endo Pharmaceuticals Inc.$131
  • Sumitomo Pharma America, Inc.$121
  • Medtronic$106
  • Myovant Sciences Inc.$97
  • plus $250 from 8 others

What the payments were for

  • Food & beverage$1,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)13$603
Johnson & Johnson4$203
Endo Pharmaceuticals Inc.3$131
Sumitomo Pharma America, Inc.6$121
Medtronic2$106
Myovant Sciences Inc.1$97
Progenics Pharmaceuticals, Inc.3$69
Tolmar, Inc.2$41
Boston Scientific1$40
Urogen Pharma, Inc.1$34
BD1$20
Civco Medical Instruments1$19
Rochester Medical Corporation1$14
Blue Earth Diagnostics1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,511 in reported general payments places this provider in the 90th percentile of 782 physician assistant providers in New Hampshire.

See all physician assistant providers in New Hampshire

Medicare billing

Part B allowed, 2024
$40,373
Medicare patients
221
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron76$47,674
GemtesaVibegron34$21,234
Trospium Chloride77$2,493
Solifenacin Succinate16$2,303
Methenamine Hippurate43$2,108
Estradiol32$1,912
Tamsulosin Hcl157$1,686
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$635
Cefdinir41$629
Finasteride26$420
Ciprofloxacin Hcl43$186
Clotrimazole14$86
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$84
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$121$21,23434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 782 physician assistant providers in New Hampshire.

Other physician assistant in Derry

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →